Amryt Pharma Holdings Ltd
LSE:AMYT

Watchlist Manager
Amryt Pharma Holdings Ltd Logo
Amryt Pharma Holdings Ltd
LSE:AMYT
Watchlist
Price: 143 GBX -11.73%
Updated: May 29, 2024

Amryt Pharma Holdings Ltd
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Amryt Pharma Holdings Ltd
Interest Income Expense Peer Comparison

Comparables:
GSK
AZN
INDV
HIK
DPH

Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Amryt Pharma Holdings Ltd
LSE:AMYT
Interest Income Expense
-$19.6m
CAGR 3-Years
-175%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
Interest Income Expense
-£641m
CAGR 3-Years
8%
CAGR 5-Years
1%
CAGR 10-Years
0%
AstraZeneca PLC
LSE:AZN
Interest Income Expense
-$1.3B
CAGR 3-Years
-2%
CAGR 5-Years
1%
CAGR 10-Years
-12%
Indivior PLC
LSE:INDV
Interest Income Expense
$9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Interest Income Expense
-$67m
CAGR 3-Years
-27%
CAGR 5-Years
-11%
CAGR 10-Years
-6%
Dechra Pharmaceuticals PLC
LSE:DPH
Interest Income Expense
-£21m
CAGR 3-Years
-34%
CAGR 5-Years
-30%
CAGR 10-Years
-14%

See Also

What is Amryt Pharma Holdings Ltd's Interest Income Expense?
Interest Income Expense
-19.6m USD

Based on the financial report for Dec 31, 2020, Amryt Pharma Holdings Ltd's Interest Income Expense amounts to -19.6m USD.

What is Amryt Pharma Holdings Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
-175%

Over the last year, the Interest Income Expense growth was -311%. The average annual Interest Income Expense growth rates for Amryt Pharma Holdings Ltd have been -175% over the past three years .